Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (2311)	12/15/2000 3:32:55 PM
From: tuck	Read Replies (1) \| Respond to of 52153

Peter, >>I guess the moral here is that the next time someone comes with a subgroup analysis, ask whether they stratified the trial on that subgroup. If they didn't, no matter what the p-value, run for the hills.<< Do you or anyone here know if any drug presented to FDA with subgroup analysis has been approved? My guess is a very narrow label and small sales would result even if one made it under those circumstances. BTW, Thanks for your recent pointer regarding analyst on Trickle (picks and shovels) plays. Cheers, Tuck